Fulcrum Therapeutics Inc

FULCNASDAQ · USD
3.75USD0.00 (+1.08%)
225

Fulcrum Therapeutics Inc (FULC) Historical Volatility

FULC's 30 day historical volatility is 20.58%, in the 18th percentile of readings over the past year. This is a low percentile, meaning Fulcrum Therapeutics Inc shares have been calmer than usual. FULC's 30 day implied volatility sits at 237.77%, with an IV Rank of 87.70%, leaving IV 217.19 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.

Read more

Tracking FULC historical volatility helps you see how much Fulcrum Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, FULC's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor FULC 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. FULC's 30 day historical volatility, or FULC HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing FULC's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.

Historical Volatility

HV Percentile
18thHV Percentile
Low

Historical movement is subdued versus the past year. The stock has been unusually quiet.

Historical Volatility (30d)20.58%

HV Percentile18th

Implied Volatility (30d)237.77%

IV Rank87.70%

IV Minus HV+217.19%

As of Nov 16, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 16, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →